C4 Therapeutics Inc
NASDAQ:CCCC
C4 Therapeutics Inc
NASDAQ:CCCC
Price:
6.24 USD
-3.55%
Market Closed
Updated:
Apr 26, 2024
Section:
Relative Value
The Relative Value of one
CCCC
stock under the Base Case scenario is
20.71
USD.
Compared to the current market price of 6.24 USD,
C4 Therapeutics Inc
is
Undervalued by 70%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CCCC
Relative Value
Base Case
20.71
USD
Undervaluation 70%
Valuation Multiples
Multiples Across Competitors
CCCC Competitors Multiples
C4 Therapeutics Inc Competitors
C4 Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
428.1m USD | 20.6 | -3.2 | -1.3 | -1.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
295.4B USD | 5.4 | 61.3 | 13.3 | 20.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
144.2B USD | 5.1 | 21.5 | 16.1 | 24.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.5B USD | 10.4 | 28.3 | 22.6 | 23.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.4B USD | 7.4 | 24.6 | 16.3 | 17.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.5B AUD | 6.2 | 35.5 | 21.5 | 26.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.3B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
40.6B USD | 5.9 | -8.6 | -9 | -7.7 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
29.3B USD | 3 | 25.3 | 13.8 | 17.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
36.9T KRW | 17 | 68.9 | 42.3 | 58.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
